Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK3 | P27361 | 7/20 | 0.71 |
| ▸ | EGFR | P00533 | 7/20 | 0.69 |
| ▸ | ALK | Q9UM73 | 4/20 | 0.69 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.67 |
| ▸ | ERBB4 | Q15303 | 2/20 | 0.67 |
| ▸ | ERBB3 | P21860 | 1/20 | 0.67 |
| ▸ | PTK2 | Q05397 | 3/20 | 0.65 |
| ▸ | INSR | P06213 | 2/20 | 0.65 |
| ▸ | IGF1R | P08069 | 2/20 | 0.65 |
| ▸ | CDC7 | O00311 | 1/20 | 0.65 |
| ▸ | PLK4 | O00444 | 1/20 | 0.65 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.65 |
| ▸ | AURKA | O14965 | 1/20 | 0.65 |
| ▸ | DCLK1 | O15075 | 1/20 | 0.65 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.65 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.65 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.65 |
| ▸ | JAK2 | O60674 | 1/20 | 0.65 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.65 |
| ▸ | PAK4 | O96013 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2593069 | 0.94 | EGFR (0.78) | MAPK3EGFRALKERBB2ERBB4 | |
| SCHEMBL18431806 | 0.88 | PTK2 (0.65) | MAPK3EGFRALKERBB2ERBB4 | |
| SCHEMBL14982967 | 0.87 | MAPK3 (0.69) | MAPK3EGFRALKPTK2INSR | |
| SCHEMBL29096017 | 0.87 | PTK2 (0.69) | MAPK3EGFRALKERBB2ERBB4 | |
| SCHEMBL13728340 | 0.87 | MAPK3 (0.71) | MAPK3EGFRALKERBB2ERBB4 | |
| SCHEMBL2594581 | 0.86 | ALK (0.76) | MAPK3EGFRALKPTK2INSR | |
| SCHEMBL15938621 | 0.85 | MAPK3 (0.83) | MAPK3EGFRALKERBB2ERBB4 | |
| SCHEMBL15948424 | 0.85 | MAPK3 (0.83) | MAPK3EGFRALKERBB2ERBB4 | |
| SCHEMBL1817282 | 0.85 | EGFR (0.68) | MAPK3EGFRALKERBB2ERBB4 | |
| SCHEMBL1532357 | 0.85 | EGFR (0.68) | MAPK3EGFRALKERBB2ERBB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160137610-A1 | Compounds that Modulate EGFR Activity and Methods for Treating or Preventing Conditions Therewith | Gatekeeper Pharmaceuticals, Inc. | 2016-05-19 | — | — | US | disclosed |
| US-20160137610-A1 | Compounds that Modulate EGFR Activity and Methods for Treating or Preventing Conditions Therewith | Gatekeeper Pharmaceuticals, Inc. | 2016-05-19 | — | — | US | disclosed |
| US-20160137610-A1 | Compounds that Modulate EGFR Activity and Methods for Treating or Preventing Conditions Therewith | Gatekeeper Pharmaceuticals, Inc. | 2016-05-19 | — | — | US | disclosed |
| US-20130137709-A1 | Compounds that modulate EGFR activity and methods for treating or preventing conditions therewith | Gatekeeper Pharmaceuticals, Inc. | 2013-05-30 | — | — | US | disclosed |
| US-20130137709-A1 | Compounds that modulate EGFR activity and methods for treating or preventing conditions therewith | Gatekeeper Pharmaceuticals, Inc. | 2013-05-30 | — | — | US | disclosed |
| US-20130137709-A1 | Compounds that modulate EGFR activity and methods for treating or preventing conditions therewith | Gatekeeper Pharmaceuticals, Inc. | 2013-05-30 | — | — | US | disclosed |
| WO-2011140338-A1 | COMPOUNDS THAT MODULATE EGFR ACTIVITY AND METHODS FOR TREATING OR PREVENTING CONDITIONS THEREWITH | Gatekeeper Pharmaceuticals, Inc. (US) | 2011-11-10 | — | — | WO | disclosed |
| WO-2011140338-A1 | COMPOUNDS THAT MODULATE EGFR ACTIVITY AND METHODS FOR TREATING OR PREVENTING CONDITIONS THEREWITH | Gatekeeper Pharmaceuticals, Inc. (US) | 2011-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160137610-A1 | Compounds that Modulate EGFR Activity and Methods for Treating or Preventing Conditions Therewith | EGFR, ERBB2, BRCA1 | MAPK3 149/4885EGFR 1/4885ALK 911/4885 |
| US-20130137709-A1 | Compounds that modulate EGFR activity and methods for treating or preventing conditions therewith | EGFR, ERBB2, BRCA1 | MAPK3 149/4885EGFR 1/4885ALK 911/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.